Relugolix

Drug Profile

Relugolix

Alternative Names: TAK-385

Latest Information Update: 02 Feb 2017

Price : $50

At a glance

  • Originator Takeda
  • Developer Myovant Sciences; Takeda; Takeda Oncology
  • Class Antineoplastics; Ketones; Pyrimidines; Small molecules
  • Mechanism of Action Gonadotropin releasing hormone inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Pain; Uterine leiomyoma
  • Phase II Endometriosis; Prostate cancer
  • Phase I Solid tumours

Most Recent Events

  • 25 Jan 2017 Phase-III clinical trials in Uterine leiomyoma (PO)
  • 25 Jan 2017 Myovant Sciences initiates enrolment in the LIBERTY 1 and LIBERTY 2 phase III trials for uterine leiomyoma
  • 25 Jan 2017 Myovant Sciences plans a phase III trial for Prostate cancer in the first half of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top